Ten63 Therapeutics Raises $15.9 Million in Oversubscribed Series A Financing to Drug the Undruggables by Combining the Power of AI and Physics-based Models
Ten63 is a Duke University start-up founded by Professor Bruce Donald (Computer Science, Trinity), and his students. Ten63 is also a Duke Capital Partners portfolio company.
April Conference Aims to Align Health Care Innovation in North Carolina
“As part of the Duke University community, we are excited about this uniquely collaborative event,” said Jeff Welch, Ph.D., director of Duke New Ventures at Duke University.
Ginkgo Bioworks Strengthens End-to-End R&D Capabilities in Gene Therapy through Acquisition of StrideBio’s AAV Capsid Discovery and Engineering Platform Assets
StrideBio was co-founded by Dr. Aravind Asokan (Surgery, SOM) and the company entered into sponsored research and licensing agreements for technology developed in his Duke lab.
Duke Capital Partners Leads Investment in Lacuna Medical
Lacuna Medical is Developing a 3D Shape Catheter that is More Resistant to Failure
Evecxia Therapeutics Reports Favorable Data From a Phase 1 Single Ascending Dose Safety/Tolerability/PK/PD Trial of EVX-301
Evecxia Therapeutics is a Duke University start-up, founded by inventors Drs. Jacob Jacobsen and Marc Caron (Cell Biology, SOM) around their serotonin synthesis amplification therapeutic technology for mental health applications.
Isolere Bio: Inside the journey of a Duke biotech start-up
From an invention in 1999, to start-up creation in 2017, to acquisition in 2023, learn of the twists and turns of Duke start-up Isolere Bio from its co-founders.
Four Points Innovation Funds Research Collaboration Between Duke University and The University of Manchester
This investment aims to accelerate research to develop a novel therapy to treat a genetic condition called Alport syndrome.
Donaldson Acquires Isolere Bio, Continuing to Build Life Sciences Business
“Isolere is thrilled to join the Donaldson family and bring our novel affinity-phase separation technology to market,” said Kelli Luginbuhl, Ph.D, co-founder and chief executive officer of Isolere.
Xilis and MD Anderson Announce Strategic Collaboration to Advance Novel Technology and Accelerate Therapeutic Development
Preclinical research agreement brings together Duke start-up Xilis' MicroOrganoSphere™ platform with MD Anderson's expertise in cancer research and therapeutic development.